Literature DB >> 16528004

Decreased plasma fibronectin leads to delayed thrombus growth in injured arterioles.

Jana Matuskova1, Anil K Chauhan, Beatrice Cambien, Sophie Astrof, Vandana S Dole, Crystal L Piffath, Richard O Hynes, Denisa D Wagner.   

Abstract

OBJECTIVE: Plasma fibronectin (FN) is decreased in several clinical conditions. We were interested to study the thrombotic and hemostatic consequences of the decrease in plasma FN (pFN), the role of FN splice variants in thrombosis, and to examine whether pFN incorporates into thrombi in vivo. METHODS AND
RESULTS: We compared the thrombotic response to a vessel injury in FN heterozygous (FN+/-) mice and corresponding FN+/+ mice. Although normal thrombosis in venules was observed, a decrease to half in the pFN concentration in FN+/- mice caused a delay in the appearance of thrombi in arterioles and consequently a delay in their occlusion. We were able to rescue the thrombotic defect in the FN+/- mice by infusion of rat pFN. Additionally, we could show intense incorporation of fluorescent pFN-coated microspheres into the developing thrombi. Moreover, we found that mice expressing FN without the EIIIA or EIIIB domains specific to cellular FN including platelet FN had no thrombotic defect.
CONCLUSIONS: Mice heterozygous for FN have a striking defect in thrombus initiation and growth in arterioles attributable to the decrease of pFN. Our study is an example of haploid insufficiency for FN, and it emphasizes the fundamental role of this plasma protein in thrombosis in the arterial system.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16528004     DOI: 10.1161/01.ATV.0000216282.58291.c6

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  17 in total

Review 1.  Fibronectin: functional character and role in alcoholic liver disease.

Authors:  Razia S Aziz-Seible; Carol A Casey
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

Review 2.  Extracellular matrix proteins in hemostasis and thrombosis.

Authors:  Wolfgang Bergmeier; Richard O Hynes
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-02-01       Impact factor: 10.005

Review 3.  Arterial thrombosis--insidious, unpredictable and deadly.

Authors:  Shaun P Jackson
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

4.  von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veins.

Authors:  Anil K Chauhan; Janka Kisucka; Colin B Lamb; Wolfgang Bergmeier; Denisa D Wagner
Journal:  Blood       Date:  2006-11-21       Impact factor: 22.113

Review 5.  Vascular wall extracellular matrix proteins and vascular diseases.

Authors:  Junyan Xu; Guo-Ping Shi
Journal:  Biochim Biophys Acta       Date:  2014-07-18

6.  The role of platelet adhesion receptor GPIbalpha far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis.

Authors:  Wolfgang Bergmeier; Crystal L Piffath; Tobias Goerge; Stephen M Cifuni; Zaverio M Ruggeri; Jerry Ware; Denisa D Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-30       Impact factor: 11.205

7.  Plasma fibronectin concentration in inbred mouse strains.

Authors:  Bianca Tomasini-Johansson; Deane F Mosher
Journal:  Thromb Haemost       Date:  2009-12       Impact factor: 5.249

8.  Elevated plasma fibronectin levels associated with venous thromboembolism.

Authors:  Natalie M Pecheniuk; Darlene J Elias; Hiroshi Deguchi; Patricia M Averell; John H Griffin
Journal:  Thromb Haemost       Date:  2008-08       Impact factor: 5.249

Review 9.  Thrombosis: tangled up in NETs.

Authors:  Kimberly Martinod; Denisa D Wagner
Journal:  Blood       Date:  2013-12-23       Impact factor: 22.113

10.  Human blood vessel-derived endothelial progenitors for endothelialization of small diameter vascular prosthesis.

Authors:  Amaresh K Ranjan; Umesh Kumar; Ashutosh A Hardikar; Pankaj Poddar; Prabha D Nair; Anandwardhan A Hardikar
Journal:  PLoS One       Date:  2009-11-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.